Pure Global
NCT06302998

Dexmedetomidine and Vasopressin in Septic Shock

Dexmedetomidine and Vasopressin (DEX-PRESSIN) for Reducing In-hospital Mortality in Septic Shock Patients: A Protocol for Randomized Controlled Trial (DecatSepsis-2)
Mansoura University·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Sepsis,Septic Shock
Drug/Device/Intervention
DEX-PRESSIN
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Mansoura University
Timeline & enrollment
Phase
Phase 2
Start date
Jun 01, 2024
End date
Jan 01, 2026
Enrollment
260 participants
Primary outcome

in-hospital mortality

Summary

Rudiger and Singer suggested strategies for refining adrenergic stress
 (decatecholaminization). They proposed the use of dexmedetomidine and vasopressin to reduce
 the catecholamine load during sepsis. The investigators will use vasopressin as the primary
 vasopressor and a heart rate-calibrated dexmedetomidine infusion in septic shock patients.
 
 The investigators of the current study will use DEXPRESSIN in septic shock patients to
 investigate the effects of decatecholaminization on in-hospital mortality.

ICD-10 classifications
Septic shockOther sepsisOther specified sepsisSepsis, unspecifiedSepsis due to other specified staphylococcus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06302998
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06302998 through Pure Global AI's free database. This Phase 2 trial is sponsored by Mansoura University and is currently Not yet recruiting. The study focuses on Sepsis,Septic Shock. Target enrollment is 260 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.